Oral GLP-1 Therapies and the Next Phase of Metabolic Disease Management
Oral GLP-1 Therapies and the Next Phase of Metabolic Disease Management Implications for Utilization Management Strategy for Health Plans By Kathryn Kolonic, DO, MBA, MPH, CPHQ